Bioline Rx Ltd ADR Dossier - Source-backed chat

Bioline Rx Ltd ADR

BLRXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.80

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $2.35Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $11.7M

Enterprise Value $17.4M

Shares Outstanding 4.8M diluted

Next Earnings Date23 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BioLineRx Ltd. represents a compelling clinical-stage biopharmaceutical opportunity with a de-risked commercial asset and a high-potential oncology pipeline. The company's lead approved product, APHEXDA (motixafortide), is commercialized globally (excluding Asia) by Ayrmid, providing growing royalty streams that offset operational cash burn. Meanwhile, the clinical pipeline is anchored by GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma (GBM), which initiated Phase 1/2a dosing in April 2026. With cash runway extending into the first half of 2027 and key clinical readouts expected in 2026 (including the Phase 2b pancreatic cancer interim analysis), BioLineRx offers asymmetric upside potential for biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$23.00

Mean target$23.00

High · most bullish analyst$23.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5020%

The Phase 2b pancreatic cancer trial fails to meet its interim efficacy/futility thresholds in 2026, halting development in solid tumors. GLIX1 encounters dose-limiting toxicities in the Phase 1 trial, delaying clinical progress. APHEXDA royalty growth flattens, forcing the company to seek dilutive equity financing or expensive debt restructuring in early 2027 to sustain operations.

Base CaseCentral scenario

$12.0050%

APHEXDA royalties continue to grow steadily, reflecting solid commercial execution by Ayrmid. The Phase 2b pancreatic cancer trial passes its interim futility analysis in 2026, keeping development on track. GLIX1 successfully completes the dose-escalation portion of its Phase 1/2a trial by late 2026/early 2027, establishing a recommended Phase 2 dose with a favorable safety profile. Cash reserves remain sufficient to fund operations into the first half of 2027, supported by modest royalty growth.

Bull CaseUpside scenario

$17.5030%

The ongoing Phase 2b CheMo4METPANC trial of motixafortide in metastatic pancreatic cancer delivers a highly positive interim efficacy readout in 2026, validating its therapeutic potential in solid tumors. Concurrently, GLIX1 demonstrates strong early safety and preliminary efficacy signals in recurrent glioblastoma, accelerating development timelines. Rapid commercial uptake of APHEXDA by Ayrmid drives royalty revenues significantly above expectations, extending the company's cash runway without requiring dilutive financing.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

De-risked commercial asset (APHEXDA) generating growing royalty revenues to offset R&D expenses.
First-in-class pipeline asset (GLIX1) targeting high-unmet-need glioblastoma with a novel DNA damage response mechanism.
Strong clinical collaborations, including the Columbia University-led Phase 2b trial supported by Regeneron.
Cash runway extending into the first half of 2027, providing near-term financial stability.

Key Investment Risks

High clinical development risk associated with early-stage oncology assets (GLIX1 Phase 1/2a).
Dependence on third-party partners (Ayrmid and Gloria Biosciences) for commercialization and regional development.
Potential need for future dilutive capital raises if royalty revenues do not scale rapidly enough to cover long-term R&D costs.

Thesis Invalidation Triggers

Failure of motixafortide to pass the Phase 2b pancreatic cancer interim futility analysis in 2026.
Severe safety signals or dose-limiting toxicities observed in the GLIX1 Phase 1/2a trial.
A significant decline in APHEXDA royalty revenues or termination of the licensing agreement by Ayrmid.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.